Latest Impairment News

Oliver’s Real Food Limited reported a 70% increase in EBIT for the June 2025 quarter, driven by cost-cutting and operational improvements, despite a nearly 6% decline in revenue due to store closures and external factors.

Resource Development Group, majority-owned by Mineral Resources, has entered voluntary administration after a funding request was declined. Mineral Resources plans to support the process but will record a significant impairment in FY25.

Mineral Resources Limited’s majority-owned Resource Development Group has entered voluntary administration, prompting MinRes to prepare for a significant non-cash impairment in its FY25 results. The unfolding administration process raises questions about the future of RDG and its impact on MinRes shareholders.

Fitzroy River Corporation reported steady royalty income for the March 2025 quarter despite operational suspensions at Buru and ongoing geopolitical risks impacting commodity markets. Key project updates include Bowdens Silver’s development application progress and Federation Mining’s Snowy River feasibility study.

Mastermyne Group forecasts a significant revenue decline for FY25 due to mine suspensions and closures but reports a stronger net cash position and early signs of operational recovery.

Lloyds Banking Group reported a robust first half in 2025, with net income up 6%, strong lending growth, and a 15% increase in its interim dividend. The bank reaffirmed its 2025 guidance and expressed confidence in meeting ambitious 2026 targets.

QuickFee Limited reports a record A$7.2 million quarterly revenue, driven by strong US and Australian growth, alongside positive underlying profitability and a major refinancing.

Bapcor reports a softer FY25 with pro-forma NPAT of $81-82 million and statutory NPAT sharply lower at $31-34 million, citing operational disruptions and a challenging retail environment. The company also announces key board resignations amid a strategic reset.

Woodside Energy reported a 2% rise in quarterly production and lowered unit costs, while the Louisiana LNG Project’s final investment decision and a major Stonepeak partnership unlock significant future value.

Firebrick Pharma has published positive Phase 3 clinical trial results for its Nasodine nasal spray, showing efficacy against the common cold, while reporting encouraging sales growth in Singapore and the US. However, a recent capital raise fell well short of targets, casting uncertainty over its expansion plans.

Amotiv Limited reports a slight decline in EBITA for FY25 alongside a significant non-cash impairment on its APG business, reflecting a cautious outlook amid challenging market conditions.

Perpetual Limited reported a 2.5% increase in assets under management to A$226.8 billion for Q4 FY25, driven by strong market performance and inflows. The company reaffirmed its expense guidance and continues to pursue the sale of its Wealth Management business.